Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity for the Development of DMD Exon 51 Skipping Therapy

Tricyclo-DNA (tcDNA) antisense oligonucleotides (ASOs) hold promise for therapeutic splice-switching applications and the treatment of Duchenne muscular dystrophy (DMD) in particular. We have previously reported the therapeutic potential of tcDNA-ASO in mouse models of DMD, highlighting their unique...

Descripción completa

Detalles Bibliográficos
Autores principales: Aupy, Philippine, Echevarría, Lucía, Relizani, Karima, Zarrouki, Faouzi, Haeberli, Adrian, Komisarski, Marek, Tensorer, Thomas, Jouvion, Grégory, Svinartchouk, Fedor, Garcia, Luis, Goyenvalle, Aurélie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063478/
https://www.ncbi.nlm.nih.gov/pubmed/31881528
http://dx.doi.org/10.1016/j.omtn.2019.11.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063478/
https://www.ncbi.nlm.nih.gov/pubmed/31881528
http://dx.doi.org/10.1016/j.omtn.2019.11.020

Ejemplares similares